Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials

doi:10.4252/wjsc.v12.i6.471

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9963)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

699

WORD

181

HTML

5345

Figures (1-2)

440

Tables (1-1)

220

Sum=6885

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

440

Download

747

Sum=1187

Publishing Process of This Article

Item

Count

Browse

658

Download

1233

Sum=1891

Jun 26, 2020 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Stem Cells. Jun 26, 2020; 12(6): 471-480
Published online Jun 26, 2020. doi: 10.4252/wjsc.v12.i6.471

Open in New Tab Full Size Figure Download Figure

Figure 1 Characteristics of clinical trials. A: Clinical phases; B: Status of trials; C: Chronological distribution; D: Geographical locations. CAN: Canada; BRZ: Brazil; EUR: Europe; EGY: Egypt; IR: Iran; RUS: Russia; CHN: China; VNM: Vietnam; AUS: Australia; Pana: Panama; JO: Jordan.

Open in New Tab Full Size Figure Download Figure

Figure 2 Respiratory diseases, types of stem cells, and administrative routes. A: Type of stem cells; B: Routes of delivery; C: Respiratory diseases. COVID-19: Coronavirus disease 2019; BPD: Bronchopulmonary dysplasia; COPD: Chronic obstructive pulmonary disease; ALI/ARDS: Acute lung injury/acute respiratory distress syndrome; PF: Pulmonary fibrosis; PAH: Pulmonary arterial hypertension; UCB-MSCs: Umbilical cord blood derived-mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cells; AD-SCs: Adipose-derived stem cells; MSCs: Mesenchymal stem cells; EPCs: Endothelial progenitor cells; PB-SC: Peripheral blood stem cells; P-MSCs: Placental mesenchymal stem cells; MSC-EV: MSC-derived extracellular vesicles; BSCs: Bronchial stem cells; MB-SCs: Menstrual blood-derived stem cells; HMPC: Human heart muscle progenitor cells; LSCs: Lung stem cells; i.v.: Intravenous; i.t.: Intratracheal; i.n.: Intranasal; PA: Pulmonary artery; s.c.: Subcutaneous; NR: Not reported.

Citation: Ji HL, Liu C, Zhao RZ. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials. World J Stem Cells 2020; 12(6): 471-480
URL: https://www.wjgnet.com/1948-0210/full/v12/i6/471.htm
DOI: https://dx.doi.org/10.4252/wjsc.v12.i6.471